Jorge Reis-Filho: A great opportunity to learn more about the exciting work being done at AstraZeneca

Jorge Reis-Filho, Vice President, Cancer Biomarker Development at AstraZeneca, shared a post by Diana Merino Vega, Director Oncology Translational Medicine Strategy and Portfolio at AstraZeneca, on LinkedIn:

“Looking forward to seeing Diana Merino Vega present how MRD assessment by ctDNA is transforming precision oncology at the National Cancer Institute’s ‘New Frontiers in Liquid Biopsies’ conference next week.

A great opportunity to learn more about the exciting work being done at AstraZeneca to drive precision medicine through innovations in liquid biopsies.”

Quoting Diana Merino Vega’s post:

“Quick reminder: David Fabrizio and I will be hosting a lunchtime session next week at the National Cancer Institute (NCI)’s conference on New Frontiers in Liquid Biopsies.

We’ll be discussing how we leverage insights of molecular residual disease (MRD) to propel precision medicine.

The field of liquid biopsy research is evolving rapidly, and I’m looking forward to discussing the potential MRD has in driving innovative solutions in this crucial area of cancer research.

You can find out more here.”

Source: Jorge Reis-Filho/LinkedIn and Diana Merino Vega/LinkedIn